Meanwhile, demand for vaccines targeting respiratory syncytial virus are down in the U.S. Also, if you are uncertain about whether you might have covid or the flu, the newly approved at-home Healgen ...

Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...

London: Pfizer recently achieved a significant legal victory by winning bid in a London court to invalidate two patents held ...

The global anti-osteoporosis therapy and fracture healing market is poised for remarkable growth, with projections indicating a rise from USD 14,051.6 million in 2023 to USD 22,427.6 million by 2033, ...

This report highlights major developments in the health sector, including WeightWatchers offering a new obesity drug, Danco ...

Current health news highlights WeightWatchers offering a compound version of Novo Nordisk's obesity drug, Danco seeking FDA ...

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.

GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...

Although not all bats carry rabies, the city's health department wants people to seek post-exposure prophylaxis if they were bitten, scratched, or had contact with a bat. Meanwhile, travelers from ...

GSK (GSK) announces that its Arexvy vaccine shows promise in protecting adults aged 60+ against RSV over three seasons in a ...

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...